JAK3-IN-18
JAK3-IN-18 is an orally active JAK3 and TEC inhibitor, with IC50s of 0.5391 nM and 12.40 nM, respectively. JAK3-IN-18 demonstrates outstanding selectivity over AK1, AK2, and TYk2, with selectivity ratios exceeding 10,000-fold. JAK3-IN-18 demonstrates excellent therapeutic efficacy in the experimental autoimmune encephalomyelitis (EAE) mouse model. JAK3-IN-18 can be used for the study of multiple sclerosis[1].
Product Specifications
CAS Number
[2914873-59-7]
UNSPSC
12352005
Target
JAK; Tyrosinase
Related Pathways
Epigenetics; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Smiles
O=C(C=C)N1CC2=C([C@@H](NC3=C4C=CNC4=NC=N3)C1)C=CC(F)=C2
Molecular Formula
C18H16FN5O
Molecular Weight
337.35
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK1; JAK2; JAK3
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
PHD3, Human, Control Peptide (PH3, Prolyl Hydroxylase Domain-containing 3, HIF2PH3, HIF-Prolyl hydroxylase 3, EGLN3, egl Nine Homolog 3, SM-20, FLJ21620)
